Want to see APVO full AI Analyst Report?
Top Page
Aptevo Therapeutics
(NASDAQ:APVO)
Select Model
Select Model
Rating:41Neutral
Price Target:
$1.00
▼(-58.51% Downside)
Action:Reiterated
Date:10/26/26
The score is held down primarily by weak financial performance (no revenue, large recurring losses, and significant cash burn implying continued external financing/dilution risk). Technicals are also bearish with the stock trading below key moving averages, despite oversold signals. Positive corporate events around clinical and platform progress provide some offset but are not enough to overcome the current financial and trend headwinds.
Positive Factors
AML Clinical Progress
Early clinical results indicate mipletamig may improve outcomes in difficult AML populations: transplant progression and reported responses support continued development. If confirmed in later studies, this could create a differentiated opportunity in a high-unmet-need setting and validate the company’s lead program.
Negative Factors
No Commercial Revenue
Aptevo has generated no reported revenue in both 2025 and 2026 TTM while posting a roughly $26.4M TTM net loss. Without commercial activity supporting the cost base, profitability visibility remains weak and the company must rely on successful development or new funding to build sustainable earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
AML Clinical Progress
Early clinical results indicate mipletamig may improve outcomes in difficult AML populations: transplant progression and reported responses support continued development. If confirmed in later studies, this could create a differentiated opportunity in a high-unmet-need setting and validate the company’s lead program.
Read all positive factors
Aptevo Therapeutics (APVO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.32M
Dividend YieldN/A
Average Volume (3M)50.10K
Price to Earnings (P/E)―
Beta (1Y)-0.05
Revenue GrowthN/A
EPS Growth99.41%
CountryUS
Employees33
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-211.18
Shares Outstanding1,810,215
10 Day Avg. Volume47,910
30 Day Avg. Volume50,099
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-0.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.38
Enterprise Value/Ebitda0.01
Forecast
1Y Price Target
$21.00Price Target Upside771.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-17.04
Revenue Forecast (FY)N/A
Aptevo Therapeutics Business Overview & Revenue Model
Company Description
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific an...
Aptevo Therapeutics Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
33
Negative
Cash Flow
8
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 3.11M | 12.29M |
| Gross Profit | -116.00K | -240.00K | -352.00K | 0.00 | 3.11M | 12.29M |
| EBITDA | -26.39M | -25.73M | -23.78M | -18.08M | 7.92M | -28.26M |
| Net Income | -26.41M | -25.97M | -24.13M | -17.41M | 8.03M | -28.46M |
Balance Sheet | ||||||
| Total Assets | 14.52M | 27.19M | 15.59M | 24.84M | 34.22M | 56.60M |
| Cash, Cash Equivalents and Short-Term Investments | 9.80M | 21.62M | 8.71M | 16.90M | 22.64M | 45.04M |
| Total Debt | 4.21M | 4.63M | 4.63M | 5.40M | 9.54M | 16.71M |
| Total Liabilities | 8.48M | 9.81M | 10.84M | 12.62M | 16.24M | 55.38M |
| Stockholders Equity | 6.04M | 17.38M | 4.75M | 12.22M | 17.97M | 1.22M |
Cash Flow | ||||||
| Free Cash Flow | -25.34M | -25.59M | -23.79M | -11.73M | -21.05M | -22.39M |
| Operating Cash Flow | -25.34M | -25.59M | -23.79M | -11.73M | -21.02M | -21.68M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -29.00K | -713.00K |
| Financing Cash Flow | 25.73M | 38.50M | 15.60M | 6.00M | -2.62M | 26.16M |
Aptevo Therapeutics Technical Analysis
Negative
2.41
Price Trends
1.94
Negative
3.14
Negative
4.48
Negative
Market Momentum
-0.16
Positive
19.70
Positive
14.89
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APVO, the sentiment is Negative. The current price of 2.41 is above the 20-day moving average (MA) of 1.69, above the 50-day MA of 1.94, and below the 200-day MA of 4.48, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 19.70 is Positive, neither overbought nor oversold. The STOCH value of 14.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APVO.
Aptevo Therapeutics Risk Analysis
Aptevo Therapeutics disclosed 58 risk factors in its most recent earnings report. Aptevo Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Our efforts to develop radiopharmaceutical product candidates may expose us to additional development, manufacturing, supply chain, regulatory and safety risks. Q2, 2026
Aptevo Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $11.02M | -0.62 | -113.79% | 0.03% | -90.65% | 26.48% | |
44 Neutral | $9.73M | -0.03 | -816.56% | ― | ― | 85.06% | |
43 Neutral | $35.54M | -1.56 | -124.21% | ― | ― | -27.34% | |
41 Neutral | $2.32M | >-0.01 | -201.49% | ― | ― | 99.41% | |
41 Neutral | $14.64M | -1.18 | -152.77% | ― | ― | 91.38% |
* Healthcare Sector Average
APVO
Aptevo Therapeutics
1.28
-25.00
-95.13%
LSTA
Lisata Therapeutics
1.02
-1.76
-63.31%
MBRX
Moleculin Biotech
9.27
-232.19
-96.16%
EDSA
Edesa Biotech
2.63
0.47
21.76%
ALLR
Allarity Therapeutics
0.92
-0.54
-36.99%
Aptevo Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Aptevo highlights promising AML transplant outcomes with mipletamig
Positive
Oct 26, 2026
On October 26, 2026, Aptevo reported that ten of forty-seven frontline acute myeloid leukemia patients initially considered unfit for intensive chemotherapy advanced to allogeneic stem cell transplant after treatment with mipletamig plus venetocla...
Business Operations and StrategyRegulatory Filings and Compliance
Aptevo Therapeutics Reports New Material Definitive Agreement
Neutral
Oct 23, 2026
In a recent filing, Aptevo Therapeutics reported that information related to its entry into a material definitive agreement has been cross-referenced within its current report on Form 8-K. The disclosure indicates that key terms of the agreement a...
Business Operations and Strategy
Aptevo to Present CD40 Multispecific Cancer Platform
Positive
Oct 14, 2026
On October 14, 2026, Aptevo Therapeutics announced plans to showcase its multispecific platform at the Society for Immunotherapy of Cancer 2026 Annual Meeting, scheduled for November 4–8, 2026, in Phoenix, Arizona. The presentation will high...
Business Operations and StrategyProduct-Related Announcements
Aptevo Advances Next-Generation Trispecific Immuno-Oncology Programs
Positive
Sep 24, 2026
On September 24, 2026, Aptevo Therapeutics announced it is advancing its next-generation trispecific immuno-oncology programs, optimizing several candidates for reliable, scalable manufacturing. The company’s lead trispecific candidate, APVO...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Aptevo Shareholders Approve Equity Issuance, Reject Charter Changes
Positive
Sep 23, 2026
On September 22, 2026, Aptevo Therapeutics stockholders held a special meeting at which they rejected proposed technical and administrative amendments to the company’s Amended and Restated Certificate of Incorporation, despite a majority of ...
Business Operations and StrategyProduct-Related Announcements
Aptevo Reports Promising Mipletamig Data in TP53-Mutant AML
Positive
Sep 3, 2026
On September 3, 2026, Aptevo Therapeutics reported new data showing a 93% clinical benefit rate for its lead drug candidate mipletamig, used in combination with venetoclax and azacitidine, in 14 evaluable frontline acute myeloid leukemia patients ...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Aptevo Shareholders Back Board, Auditor and Incentive Plan
Positive
Aug 21, 2026
On August 21, 2026, Aptevo Therapeutics Inc. held its Annual Meeting of Stockholders, at which shareholders elected Zsolt Harsanyi, Ph.D., and Barbara Lopez Kunz to the board to serve until the 2029 annual meeting, and ratified Baker Tilly US, LLP...
Private Placements and Financing
Aptevo Therapeutics Raises Capital Through Warrant-Induced Financing
Neutral
Aug 13, 2026
On August 12, 2026, Aptevo Therapeutics entered into warrant inducement agreements and a securities purchase agreement with certain existing warrant holders, leading to the exercise of prior warrants at a reduced price of $4.03 per share and the i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.